These two medicines are compared constantly for hair loss, but they are not licensed for the same thing. Finasteride, as Propecia, is indicated for the treatment of male pattern hair loss in men only. Dutasteride, as Avodart, is indicated for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate. Hair loss is not on the dutasteride label.

That single fact reframes the whole comparison, and it is missing from most articles that make it. A comparison between a licensed treatment and an unlicensed use is a legitimate thing to discuss, but only if it says that is what it is.

Key takeaways

  • Both are 5-alpha-reductase inhibitors, which is why they get compared.
  • Only finasteride is licensed for hair loss, and in men only.
  • Dutasteride is licensed for symptomatic benign prostatic hyperplasia, to improve symptoms in men with an enlarged prostate.
  • Both labels carry the class warning that 5-alpha-reductase inhibitors may increase the risk of high-grade prostate cancer.
  • Neither is approved for preventing prostate cancer. Dutasteride’s label states this as an explicit limitation of use.
  • Both affect PSA results, so any doctor testing your PSA must know you take one.
  • Both carry pregnancy restrictions, and dutasteride’s extends to handling the capsules at all.
  • Using an unlicensed option is a clinical decision, made with a doctor who knows your history, not a self-directed upgrade.

What is each one actually approved to treat?

Different conditions, and the labels are explicit.

Finasteride (Propecia). The label states it is “a 5α-reductase inhibitor indicated for the treatment of male pattern hair loss (androgenetic alopecia) in MEN ONLY”, and adds that it “is not indicated for use in women”. The emphasis on men only is the label’s own.

Dutasteride (Avodart). The label states it is “a 5 alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate” to improve symptoms. Its stated purpose is the prostate, not the scalp.

Finasteride is also used at a higher strength for enlarged prostate, which is why the same ingredient appears in two different products at two different strengths. That is worth knowing if you are matching a prescription across countries: the strength tells you which use it was prescribed for.

Why do people compare them for hair loss at all?

Because both block 5-alpha-reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT), and DHT is central to male pattern hair loss. Propecia’s label describes finasteride as a “competitive and specific inhibitor of Type II 5α-reductase” and states that it decreases scalp and serum DHT concentrations. Since dutasteride also acts on this pathway, the question of whether it might do more for hair keeps returning.

An approval is not settled by that logic. A medicine reaches a licensed indication by demonstrating benefit and an acceptable risk balance for that specific use in a review by a regulator. Dutasteride has done that for enlarged prostate. For hair loss, the use is off-label, and the prescriber is choosing to accept a risk profile that was assessed for a different purpose.

Any article that presents this as simply “the stronger option” has skipped the part that matters.

What is the prostate cancer risk?

Both labels carry the class warning about high-grade prostate cancer. The Propecia prescribing information states in Warnings and Precautions 5.3: “5α-reductase inhibitors may increase the risk of high-grade prostate cancer” (Propecia prescribing information (DailyMed)). It also reports that in the 7-year Prostate Cancer Prevention Trial, the incidence of Gleason score 8-10 prostate cancer was higher with finasteride (1.8%) than with placebo (1.1%). The Avodart label carries the same class warning and states:

  • “AVODART may increase the risk of high-grade prostate cancer.”
  • “Limitations of Use: AVODART is not approved for the prevention of prostate cancer.”

High-grade prostate cancer is the more aggressive form. The class warning appears on both labels, so the contrast is not that finasteride’s hair-loss label omits it. Dutasteride’s label separately states that Avodart is not approved for the prevention of prostate cancer.

This is not a reason to refuse dutasteride if you have been prescribed it for an enlarged prostate, where the benefit was assessed against exactly this risk. It is a reason to have the conversation explicitly if it is being considered for cosmetic use.

What do they both do to PSA testing?

Both lower PSA, which can make a prostate cancer screening result look better than it is. In clinical studies with Propecia in men aged 18 to 41, mean serum PSA decreased from 0.7 ng/mL at baseline to 0.5 ng/mL at Month 12. Any confirmed increase from the lowest PSA value while on Propecia may signal the presence of prostate cancer and should be evaluated, even if PSA levels are still within the normal range for men not taking a 5-alpha-reductase inhibitor. The dutasteride label makes the same point. The result therefore needs to be read by a doctor who knows the medicine is being taken.

The doctor arranging the test needs to know before the result is read. A confirmed rise from the lowest value on treatment can signal prostate cancer even if the number is still within the normal range for men not taking one of these. Pregnancy and handling are restricted on both labels, with the dutasteride wording being stricter.

What about pregnancy and handling?

Both labels carry pregnancy-related restrictions, but the handling wording is different.

  • Finasteride: Propecia tablets are film-coated, so normal handling prevents contact with the active ingredient, provided the tablets have not been broken or crushed. Women should not handle crushed or broken Propecia tablets when they are pregnant or may potentially be pregnant because of the possible risk to a male fetus (Propecia prescribing information (DailyMed)).
  • Dutasteride: use is contraindicated in women who are pregnant, and women who are or may be pregnant should not handle the capsules at all.

The difference is meaningful in a shared household. An intact finasteride tablet is not the handling concern; a broken one is. A dutasteride capsule is a concern regardless of whether it is intact.

So which should I take?

The choice is a prescriber’s decision and starts with what you are treating. For male pattern hair loss, finasteride is the option licensed for it, with the evidence assessed for that use. For an enlarged prostate, both are used, and dutasteride is licensed for it. If dutasteride is being suggested for hair loss, ask directly whether it is being used off-label, why it is preferred over the licensed option in your case, and how the high-grade prostate cancer statement applies to you.

More potent does not mean better. A stronger effect on the same system can also mean a stronger effect on the risks.

Do and don’t

Do:

  • Establish what you are treating before comparing medicines.
  • Ask whether a proposed use is on-label or off-label.
  • Tell any doctor testing your PSA that you take one of these.
  • Store both away from anyone who is or may be pregnant.
  • Ask what happens when you stop, since neither is curative.

Don’t:

  • Assume the more potent medicine is the better choice.
  • Treat a hair clinic’s comparison as a clinical assessment.
  • Switch between them yourself.
  • Read a normal PSA on treatment as automatic reassurance.

Frequently asked questions

Is dutasteride simply a stronger finasteride? They act on the same enzyme system with different profiles, but the difference that matters for a decision is not potency. It is that they hold different licensed indications and carry different label warnings. Potency without an approved indication for your condition is not an advantage.

Can women take either for hair loss? No. Propecia’s label states it is not indicated for use in women, and the NHS hair loss page says women should not use finasteride. For female pattern baldness, the NHS main treatment listed is minoxidil. Dutasteride is contraindicated in pregnancy and carries handling restrictions.

If I stop, do I keep the hair? No. The Propecia label states that withdrawal of treatment leads to reversal of effect within 12 months. Neither addresses the underlying process, so the benefit reverses after stopping. That is true of both.

Where to go next

The broader picture, including non-drug options and why a diagnosis should come first, is in hair loss treatment. NHS guidance is to see a GP to get an idea about what is causing your hair loss before considering a commercial hair clinic. The hair loss and prostate health categories list what is stocked here, since finasteride and dutasteride sit across both.

MedicForce option: our listings show active ingredient and strength, which is what separates the hair-loss product from the prostate one for the same ingredient.

Label statements quoted above are from the approved product information for Propecia (finasteride) and Avodart (dutasteride).